Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan

  • Yoshihiro Shibata
  • Hiroshi Ariyama
  • Eishi BabaEmail author
  • Yasushi Takii
  • Taito Esaki
  • Kenji Mitsugi
  • Tanji Tsuchiya
  • Hitoshi Kusaba
  • Koichi Akashi
  • Shuji Nakano
Original Article



Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC. With the increasing use of oxaliplatin in Japan, serious adverse events have been experienced other than hematologic and neurologic toxicities.


In order to clarify the clinical features of allergic reactions to oxaliplatin, we retrospectively investigated CRC patients who had received oxaliplatin-based chemotherapies.


One hundred and twenty-five CRC patients who had been treated with FOLFOX regimens (containing oxaliplatin, 5-FU, and LV) were examined, and 21 patients (17%) were found to have developed allergic reactions. Sixteen patients (13%) had grade 1/2 adverse events, classified according to the common terminology criteria for adverse events (CTC-AE) version 3.0 and 5 (4%) had grade 3/4 adverse events. The allergic reaction appeared after a median number of nine cycles (range, 2–15 cycles). Previous chemotherapy included 5-FU/LV, CPT-11, and S-1. All of the patients with allergic reactions recovered completely when treated with antiallergy drugs. Oxaliplatin was reintroduced in 11 patients, with the use of prophylactic agents; allergic reaction to the reintroduction was not observed in 8 patients and grade 1/2 allergic reactions developed in 3 patients. No correlation was identified between allergic reaction and patients’ background characteristics such as sex, history of allergy, and profile of other adverse events.


Allergic reactions to oxaliplatin remain an important issue for patients being able to safely continue effective chemotherapies; further analysis will be needed to establish methods for the prediction and prophylaxis of such reactions.

Key words

Colorectal cancer Oxaliplatin Allergic reaction 


  1. 1.
    De Gramont A, Figer A, Seynour M, et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMedGoogle Scholar
  2. 2.
    Goldberg RM, Sargent D, Morton RF, et al. (2004) N9741: FOLFOX (oxaliplatin (Oxal)/5-FU/leukovorin (LV)) or reduced dose R-Ifl(CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from an Intergroup Study. J Clin Oncol 23:275 (Suppl; abstract 3621)Google Scholar
  3. 3.
    Tvagi P, Grothey A (2006) Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Clin Colorectal Cancer 6:261–264CrossRefGoogle Scholar
  4. 4.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. (2004) Multicenter international study of oxaliplatin/5-fluorouracil/leukovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators: oxaliplatin, fluorouracil and leukovorin as adjuvant treatment for colon cancer. N Engl J Med 50:2243–2251Google Scholar
  5. 5.
    Thomas RR, Quinn MG, Schuler B, et al. (2003) Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 97:2301–2307CrossRefPubMedGoogle Scholar
  6. 6.
    Siu SW, Chan RT, Au GK (2006) Hypersensitivity reactions to oxaliplatin:experience in a single institute. Ann Oncol 17:2590–2261Google Scholar
  7. 7.
    Maindrault-Goebel F, Andre T, Tournigand C, et al. (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 41:2262–2267CrossRefPubMedGoogle Scholar
  8. 8.
    Gowda A, Goel R, Berdzik J, et al. (2004) Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology 18: 1671–1675PubMedGoogle Scholar
  9. 9.
    Brandi G, Pantaleo MA, Galli C, et al. (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89:477–481CrossRefPubMedGoogle Scholar
  10. 10.
    Shleback AA, Clark PI, Green JA, et al. (1995) Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 35:349–351CrossRefGoogle Scholar
  11. 11.
    Koren C, Yerushalmi R, Katz A, et al. (2002) Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol 25:625–626CrossRefPubMedGoogle Scholar
  12. 12.
    Basu R, Rajkumar A, Datta NR (2002) Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol 7:365–367CrossRefPubMedGoogle Scholar
  13. 13.
    Polyzos A, Tsavaris N, Kosmas C, et al. (2001) Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61:129–133CrossRefPubMedGoogle Scholar
  14. 14.
    Zanotti KM, Rybicki LA, Kennedy AW, et al. (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126–3129PubMedGoogle Scholar
  15. 15.
    Stahl M, Koster W, Wikle H (2001) Reaction after oxaliplatin — prevention with corticosteroids? Ann Oncol 12:874CrossRefPubMedGoogle Scholar
  16. 16.
    Morgan JS, Adams M, Mason MD (1994) Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 30:1205–1206CrossRefGoogle Scholar
  17. 17.
    Santini D, Tonini G, Salerno A, et al. (2001) Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 12:132–133CrossRefPubMedGoogle Scholar
  18. 18.
    Newman Taylor AJ, Cullinan P, Lympany PA, et al. (1999) Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Respir Crit Care Med 160: 435–438PubMedGoogle Scholar
  19. 19.
    Markmen M, Kennedy A, Webster K, et al. (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17: 1141–1145Google Scholar
  20. 20.
    Sliesoraitis S, Chikhale PJ (2005) Carboplatin hypersensitivity. Int J Gynecol Cancer 15:13–18CrossRefPubMedGoogle Scholar
  21. 21.
    Lee MY, Yang MH, Liu JH (2007) Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 15:89–93CrossRefPubMedGoogle Scholar
  22. 22.
    Mis L, Fernando NH, Hurwitz HI, et al. (2005) Successful desensitization to oxaliplatin. Ann Pharmacother 39:966–969CrossRefPubMedGoogle Scholar
  23. 23.
    Tournigand C, Cervantes A, Figer A, et al. (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — a GERCOR study. J Clin Oncol 24:394–400CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2009

Authors and Affiliations

  • Yoshihiro Shibata
    • 1
  • Hiroshi Ariyama
    • 2
  • Eishi Baba
    • 1
    Email author
  • Yasushi Takii
    • 1
  • Taito Esaki
    • 2
  • Kenji Mitsugi
    • 3
  • Tanji Tsuchiya
    • 4
  • Hitoshi Kusaba
    • 1
  • Koichi Akashi
    • 1
  • Shuji Nakano
    • 1
  1. 1.Department of Medicine and Biosystemic ScienceKyushu University Graduate School of Medical SciencesFukuokaJapan
  2. 2.Department of Gastrointestinal and Medical OncologyNational Hospital Organization Kyushu Cancer CenterFukuokaJapan
  3. 3.Department of Medical OncologyHamanomachi HospitalFukuokaJapan
  4. 4.Department of Internal MedicineSawara HospitalFukuokaJapan

Personalised recommendations